Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03442062 · ClinicalTrials.gov registry record · NA
Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 264
- Enrollment target
NCT03442062: Completed NA study, sponsored by University of North Carolina, Chapel Hill.
NCT03442062 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 264 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03442062, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 264 participants
- Enrollment target
Study Summary
HPV vaccination is at lower levels than the national goals. This study will evaluate the effectiveness of quality improvement strategies for increasing HPV vaccination coverage among adolescents in primary care clinics.
Primary Outcome
Coverage change from baseline to twelve months in HPV vaccine initiation (≥1 dose), among 11- to 12- year old patients, as measured by states' immunization information system (IIS) records
Interventions
- OTHER Assessment Feedback Incentives and eXchange
- OTHER Physician-to-physician engagement
- OTHER Active Intervention Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2020-04-30 |
| Phase | NA |
What the finished NCT03442062 record still lists
NCT03442062 is an interventional study that assigns participants to a tested intervention. The registered 264 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 3 interventions - of which Assessment Feedback Incentives and eXchange is the first listed.
NCT03442062 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03442062 about?
NCT03442062 is a clinical study titled "Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination". HPV vaccination is at lower levels than the national goals. This study will evaluate the effectiveness of quality improvement strategies for increasing HPV vaccination coverage among adolescents in primary care clinics.
What is the current status of trial NCT03442062?
This trial is currently completed. It is a NA study. The enrollment target is 264 participants. The study started on 2018-05-07. Estimated completion is 2020-04-30.
What interventions are being tested in trial NCT03442062?
The interventions under investigation include: Assessment Feedback Incentives and eXchange (OTHER), Physician-to-physician engagement (OTHER), Active Intervention Control (OTHER).
Who is sponsoring clinical trial NCT03442062?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03442062's enrollment target sits among peer trials
264 395th of 2000 higher than 1,605 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
- NCT04295863 · 264 participants · Phase 1
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- NCT05220202 · 264 participants · NA
MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression
- NCT05473013 · 264 participants · NA
Optimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI